MariTide for weight loss and diabetes

We are entering a golden age for biotech companies and Vestact-recommended stock Amgen is not being left behind. There are three major innovations in progress now: (1) advancements in AI and deep learning, (2) significant cost reductions for collecting biological data through lab automation, and (3) the precision editing of DNA with CRISPR.

Amgen is not just investing in cutting-edge research and development, they are also rolling out new high-tech manufacturing facilities. They just opened a massive plant in New Albany, Ohio, that cost almost $500 million to build. They aim to produce injectables there, including the new weight-loss drug MariTide (once it's approved by the FDA).

Goldman Sachs reckons that Amgen should be trading at $350 per share (it's at $286 now) on the basis of its "catalyst-rich" pipeline of new obesity, immunology, inflammation, and cancer drugs. Sounds good, we will go along for the ride.